advertisement
Abstract #8959 Published in IGR 5-2
Study on hypotensive effect of latanoprost vs timolol-dorzolamide association
Luque-Aranda R; Cabarga Del Nozal C; Silva-Silva G; Vazquez-Salvi A; Garcia-Campos JMArchivos de la Sociedad Española de Oftalmologia 2002; 77: 205-210
PURPOSE: To compare hypotensive effect of latanoprost versus timolol-dorzolamide association on patients with glaucoma. MATERIAL AND METHODS: The authors studied 102 eyes in 52 patients with intraocular pressure (IOP) higher than 21 mmHg, previously treated with a beta blocker. Patients were divided into two groups. Treatment was changed in group 1 (51 eyes of 27 patients) to a timolol-dorzolamide association. Group 2 (51 eyes of 27 patients) changed treatment to latanoprost. After determination of previous IOP, readings were taken after one, three, and eight months. RESULTS: Both groups showed a decrease in IOP levels: Group 1, 5.6 mmHg and Group 2, 8.5 mmHg. Association between timolol and dorzolamide reached the highest hypotensive effect after the first month of treatment and remained constant during the remainder of the study period. Latanoprost showed a maximal effect after the third month of treatment and maintained its effect throughout the study as well. Latanoprost behaved similarly to associated timolol-dorzolamide, not showing significant differences during the first month of treatment. Significant differences appeared at third and eighth months, favoring latanoprost (p < 0.005 and p < 0.001 respectively). CONCLUSIONS: There was a similarity in efficacy of both treatments. However, after the third month latanoprost became more effective than the timolol-dorzolamide association. LA: Spanish
Dr. R. Luque-Aranda, Servicio de Oftalmologia, Hospital Universitario Virgen de la Victoria, Facultad de Medicina, Malaga, Spain. luqueoliva@hotmail.com
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
